Tocilizumab desensitization therapy of refractory systemic juvenile idiopathic arthritis: a case report and literature review
10.3760/cma.j.cn101070-20240816-00520
- VernacularTitle:托珠单抗脱敏治疗难治性全身型幼年特发性关节炎1例及文献复习
- Author:
Yandie LI
1
;
Qi ZHENG
1
;
Yiping XU
1
;
Meiping LU
1
;
Lixia ZOU
1
Author Information
1. 浙江大学医学院附属儿童医院风湿免疫过敏科，国家儿童健康与疾病临床医学研究中心，杭州 310052
- Publication Type:Journal Article
- Keywords:
Tocilizumab;
Systemic juvenile idiopathic arthritis;
Desensitization therapy
- From:
Chinese Journal of Applied Clinical Pediatrics
2025;40(3):220-222
- CountryChina
- Language:Chinese
-
Abstract:
The clinical data of a child with refractory systemic juvenile idiopathic arthritis (sJIA) who was admitted to the Children′s Hospital, Zhejiang University School of Medicine in October 2023 were analyzed, and literature review was conducted.The patient was a 9-year-old boy, who was admitted due to recurrent fever, accompanied by rash and joint pain for more than 4 years.Four years ago, he was diagnosed with macrophage activation syndrome and sJIA.In the past 4 years, the condition recurred 3 times under treatment with glucocorticoids, Cyclosporine, and Methotrexate.He previously experienced allergic shock after 5 minutes of infusion of Tocilizumab.Due to Tocilizumab allergy, he was treated with Janus kinase inhibitors, but the disease still recurred.After informed consent was obtained from the guardian, 240 mg of Tocilizumab was administrated for desensitization once every 2 weeks and the process went smoothly.The patient has been followed up for more than 6 months and no allergic reactions had occurred.The condition was well controlled, and the Prednisone acetate tablet had been reduced to 2.5 mg orally once a day.At present, there are 10 patients undergoing desensitization treatment both domestically and internationally, including 2 males and 8 females, aged between 2.5 and 54.0 years.All of them have achieved a success in desensitization.Therefore, Tocilizumab desensitization therapy is of great significance for patients who are allergic to biologics in clinical practice.
